Initiated registrational Phase 2b SAFEGUARD trial of SAB-142 in new-onset, Stage 3 autoimmune T1D patientsMultiple SAFEGUARD trial sites ...

Vittoria Biotherapeutics, Inc., a clinical-stage immunotherapy company pioneering innovative cell therapies, today announced ...

ERS Genomics Limited (‘ERS’), the CRISPR licensing company, and Dyadic Applied BioSolutions, a global biotechnology company producing precision-engineered, animal-free proteins and enzymes for diverse ...

Presentation of MyPEAK-1 Data and the American Heart Association Scientific Sessions Showed Consistent, Deeper, and Durable ...

The Family Heart Foundation, the leading research, education and advocacy organization focused on genetic dyslipidemias, today announced it will share key research findings and data at the 2025 ...

TAPS+ enables simultaneous detection of methylation and genetic variants, unlocking new insights for precision oncology and translational research. Preserves DNA integrity in challenging clinically ...

In this GEN webinar, Nathan Buchbinder and Ritida Nanda will discuss how Proscia Aperture™, powered by the Concentriq® enterprise pathology platform and global network of diagnostic labs, transforms ...

Details of the TN-201 clinical data presentation are as follows: ...

Johns Hopkins University School of Medicine alumnus and former faculty member Hamilton O. Smith, M.D., whose 1978 Nobel Prize ...

Details of the novel pharmacokinetic assay for measuring SAB-142.

First company to enable precision in vivo genome engineering, combining both cell-specific delivery and programmable, locus-specific gene insertion, with the potential to achieve physiological, durabl ...

Should we genetically modify wild lions? Of course not, might be your instant response. But what if lions were being wiped out by a devastating disease introduced by people? What if the genetic change ...